Characteristics | irAE cohort n (%) | NirAE cohort n (%) | |
---|---|---|---|
38 (38) | 61 (62) | ||
67.4 | 61.6 | ||
Male | 18 (47.4) | 37 (60.7) | |
Female | 20 (52.6) | 24 (39.3) | |
Naive | 34 (89.5) | 51 (83.6) | |
Previously treated | 4 (10.5) | 10 (16.4) | |
Pembrolizumab | 34 (89.5) | 52 (85.2) | |
Nivolumab | 2 (5.3) | 5 (8.2) | |
Nivolumab + ipilimumab | 2 (5.3) | 4 (6.6) | |
BRAF mutated | 10 (26.3) | 17 (27.9) | |
BRAF wild type | 21 (55.3) | 27 (44.3) | |
Not reported | 7 (18.4) | 17 (27.9) | |
Cohort a and b | 22 (57.9) | 35 (57.4) | |
Cohort c and d | 16 (42.1) | 26 (42.6) | |
increased | 7 (18.4) | 15 (24.6) | |
normal | 31 (81.6) | 46 (75.4) |